Precision Biosciences Inc.
DTIL Nasdaq
SEC CIK 1357874
Follow Precision Biosciences
Weekly email: filings, results
Revenue, last quarter
$0
−100% vs same quarter last year
Net income
−$7.6M
+65.2% vs same quarter last year
EPS, diluted
−$0.28
+84.8% vs same quarter last year
Operating cash flow
−$15.1M
+0.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $34.3M | −$45.7M |
| FY24 | $68.7M | $7.2M |
| FY23 | $48.7M | −$61.3M |
| FY22 | $25.1M | −$111.6M |
| FY21 | $115.5M | −$30.6M |
| FY20 | $24.3M | −$109M |
| FY19 | $22.2M | −$92.9M |
| FY18 | $10.9M | −$46M |
| FY17 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −152.2% | −133.4% |
| FY24 | −38.1% | 10.4% |
| FY23 | −89.8% | −125.8% |
| FY22 | −248.3% | −444.8% |
| FY21 | −34.1% | −26.5% |
| FY20 | −452.2% | −448.9% |
| FY19 | −392.1% | −417.6% |
| FY18 | −440.2% | −423% |
| FY17 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$65.9M |
| FY24 | −$58.7M |
| FY23 | −$86.1M |
| FY22 | −$49.1M |
| FY21 | −$15.9M |
| FY20 | −$92.4M |
| FY19 | −$95.7M |
| FY18 | −$66M |
| FY17 | - |
- Precision Biosciences
- Healthcare median
Show the numbers
| Year | Precision Biosciences | Healthcare median |
|---|---|---|
| FY25 | −133.4% | −30.6% |
| FY24 | 10.4% | −47% |
| FY23 | −125.8% | −58% |
| FY22 | −444.8% | −80.4% |
| FY21 | −26.5% | −71.8% |
| FY20 | −448.9% | −62.2% |
| FY19 | −417.6% | −46.2% |
| FY18 | −423% | −49.6% |
| FY17 | - | −45.9% |